Urinary Tract Infection Treatment Market Report 2026

The urinary tract infection treatment market size has grown steadily in recent years. It will grow from $10.76 billion in 2025 to $11.12 billion in 2026 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to rising prevalence of recurrent UTIs, increased antibiotic prescription rates, improved access to primary healthcare services, growing awareness of urinary infections, availability of diverse antimicrobial drug classes.

The urinary tract infection treatment market size is expected to see steady growth in the next few years. It will grow to $12.9 billion in 2030 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to increasing development of resistance-aware therapies, rising investments in novel antibiotics, expansion of rapid point-of-care diagnostics, growing focus on personalized infection treatment, increased adoption of telemedicine-based UTI management. Major trends in the forecast period include increasing adoption of broad-spectrum antibiotics, rising focus on rapid diagnostic testing, growing demand for targeted antimicrobial therapies, expansion of outpatient uti treatment options, enhanced emphasis on antimicrobial stewardship.

The increasing prevalence of urinary tract infections is expected to drive the growth of the urinary tract infection treatment market. Urinary tract infections are bacterial infections that can affect the kidneys, bladder, ureters, urethra, and other parts of the urinary system. Treatment of urinary tract infections is crucial, as it helps manage the infection and supports healing. For example, in January 2023, the National Institutes of Health, a US-based public health research agency, reported that urinary tract infections were the seventh most common reason for emergency department visits in the United States, accounting for over one million visits annually. Of these, 22% (220,000) were classified as complicated UTIs, and approximately 100,000 patients required hospitalization each year. Consequently, the rising incidence of urinary tract infections is driving growth in the urinary tract infection treatment market.

Key players in the urinary tract infection treatment market are focusing on introducing next-generation therapies, such as first-in-class oral antibiotics, to enhance treatment outcomes and combat increasing antimicrobial resistance. First-in-class oral antibiotics are novel antibacterial agents with new mechanisms of action, developed to treat uncomplicated UTIs caused by both common and drug-resistant uropathogens, offering alternatives to older antibiotics with diminished effectiveness. For instance, in March 2025, UK-based GlaxoSmithKline (GSK) received FDA approval in the U.S. for Blujepa (gepotidacin), an antibiotic for treating uncomplicated urinary tract infections in women and girls aged 12 years and older. Blujepa employs a completely new bacterial topoisomerase-inhibition mechanism, shows efficacy against drug-resistant Escherichia coli, and is administered as a single-dose oral regimen, marking a significant advancement in UTI therapy.

In July 2025, Alembic Pharmaceuticals Inc., a US-based subsidiary of Indian multinational Alembic Pharmaceuticals Ltd., acquired Utility Therapeutics for $0.012 billion. Through this acquisition, Alembic aims to expand its U.S. branded specialty pharmaceuticals portfolio by incorporating Utility Therapeutics’ FDA-approved drug PIVYA (pivmecillinam) for the treatment of uncomplicated urinary tract infections. Utility Therapeutics Ltd. is a UK-based biopharmaceutical company specializing in UTI therapies.

Major companies operating in the urinary tract infection treatment market are Pfizer Inc., Merck & Co Inc, Bayer AG, Sanofi S A, AstraZeneca plc, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddy’s Laboratories Ltd, Cipla Ltd, Hikma Pharmaceuticals PLC, Lupin Limited, Torrent Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Mylan N V, Aurobindo Pharma Ltd, Macleods Pharma Ltd, Zydus Cadila Healthcare Ltd, Abbott Laboratories, Shionogi & Co Ltd, Alkem Laboratories Ltd.

North America was the largest region in the urinary tract infection treatment market in 2025. The regions covered in the urinary tract infection treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urinary tract infection treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the urinary tract infection treatment market by increasing costs of imported antibiotics, active pharmaceutical ingredients, diagnostic kits, and laboratory equipment. Healthcare providers in North America and Europe are most affected due to reliance on global pharmaceutical supply chains, while Asia-Pacific faces cost pressures on antibiotic exports. These tariffs are influencing drug pricing and availability across retail and hospital pharmacies. At the same time, they are encouraging domestic antibiotic manufacturing, regional API production, and localized development of cost-effective UTI treatment solutions.

The urinary tract infection treatment market research report is one of a series of new reports that provides urinary tract infection treatment market statistics, including urinary tract infection treatment industry global market size, regional shares, competitors with a urinary tract infection treatment market share, detailed urinary tract infection treatment market segments, market trends and opportunities, and any further data you may need to thrive in the urinary tract infection treatment industry. This urinary tract infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Urinary tract infection treatment refers to the medical procedures and methods used to eliminate bacterial infections affecting the urinary system. Urinary tract infections can impact the bladder, urethra, ureters, kidneys, and other parts of the urinary system.

The main drug classes used in urinary tract infection treatment include penicillin and its combinations, quinolones, cephalosporins, aminoglycoside antibiotics, sulphonamides, azoles and amphotericin B, tetracyclines, and nitrofurantoin. Penicillin is a beta-lactam antibacterial medication used to treat a wide range of infections. In the treatment of urinary tract infections, penicillin is effective against the common bacteria responsible for UTIs and is generally well tolerated. The primary indications include both complicated and uncomplicated UTIs. Distribution channels for these treatments include hospital pharmacies, gynecology and urology clinics, drug stores, retail pharmacies, and online pharmacies.

The urinary tract infection treatment market consists of sales of trimethoprim, sulfamethoxazole, cephalexin, and ceftriaxone. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.